In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $56.18 in the last session, up 1.59% from day before closing price of $55.3. In other words, the price has increased by $1.59 from its previous closing price. On the day, 1.54 million shares were traded. CRSP stock price reached its highest trading level at $56.64 during the session, while it also had its lowest trading level at $54.12.
Ratios:
We take a closer look at CRSP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 16.22 and its Current Ratio is at 16.22. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In the most recent recommendation for this company, JP Morgan on September 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On February 14, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $60 to $99.
TD Cowen Upgraded its Sell to Hold on February 12, 2025, while the target price for the stock was maintained at $35.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 06 ’26 when Prasad Raju sold 29,700 shares for $60.16 per share. The transaction valued at 1,786,636 led to the insider holds 6,767 shares of the business.
RAJU PRASAD bought 29,700 shares of CRSP for $1,786,636 on Jan 06 ’26. On Dec 22 ’25, another insider, Prasad Raju, who serves as the Chief Financial Officer of the company, sold 10,000 shares for $55.95 each. As a result, the insider received 559,549 and left with 6,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5353967104 and an Enterprise Value of 3649281024. For the stock, the TTM Price-to-Sale (P/S) ratio is 139.64 while its Price-to-Book (P/B) ratio in mrq is 2.75. Its current Enterprise Value per Revenue stands at 95.19 whereas that against EBITDA is -7.942.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.72, which has changed by 0.41649592 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $78.48, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is 1.81%, while the 200-Day Moving Average is calculated to be 7.79%.
Shares Statistics:
According to the various share statistics, CRSP traded on average about 2.13M shares per day over the past 3-months and 1766490 shares per day over the past 10 days. A total of 93.87M shares are outstanding, with a floating share count of 91.55M. Insiders hold about 3.94% of the company’s shares, while institutions hold 71.25% stake in the company. Shares short for CRSP as of 1767139200 were 21051418 with a Short Ratio of 9.91, compared to 1764288000 on 22431985. Therefore, it implies a Short% of Shares Outstanding of 21051418 and a Short% of Float of 24.8.
Earnings Estimates
Currently, 17.0 analysts are dedicated to thoroughly evaluating and rating the performance of CRISPR Therapeutics AG (CRSP) in the stock market.The consensus estimate for the next quarter is -$1.1, with high estimates of -$0.87 and low estimates of -$1.25.
Analysts are recommending an EPS of between -$4.97 and -$6.86 for the fiscal current year, implying an average EPS of -$6.19. EPS for the following year is -$4.46, with 19.0 analysts recommending between -$2.01 and -$6.22.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $27.6M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $6.22M. In the same quarter a year ago, actual revenue was $37.31M
